Abstract
Bladder cancer is the fifth most common cancer in the United States. Most bladder cancers are early-stage lesions confined to the mucosa or submucosa and are therefore classified as non-muscle-invasive bladder cancer (NMIBC). A minority of tumors are diagnosed after they have invaded the underlying detrusor muscle and are classified as muscle-invasive bladder cancer (MIBC). Mutational inactivation of the STAG2 tumor suppressor gene is common in bladder cancer, and we and others have recently demonstrated that STAG2 mutation status can be used as an independent prognostic biomarker to predict whether NMIBC will recur and/or progress to MIBC. Here we describe an immunohistochemistry-based assay for identifying the STAG2 mutational status of bladder tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30. https://doi.org/10.3322/canjclin.55.1.10
Chang SS, Boorjian SA, Chou R et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196(4):1021–1029. https://doi.org/10.1016/j.juro.2016.06.049
Solomon DA, Kim T, Diaz-Martinez LA et al (2011) Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333(6045):1039–1043. https://doi.org/10.1126/science.1203619
Waldman T (2020) Emerging themes in cohesin cancer biology. Nat Rev Cancer 20(9):504–515. https://doi.org/10.1038/s41568-020-0270-1
Kim Y, Shi Z, Zhang H et al (2019) Human cohesin compacts DNA by loop extrusion. Science 366(6471):1345–1349. https://doi.org/10.1126/science.aaz4475
Davidson IF, Bauer B, Goetz D et al (2019) DNA loop extrusion by human cohesin. Science 366(6471):1338–1345. https://doi.org/10.1126/science.aaz3418
Rao SSP, Huang SC, Glenn St Hilaire B et al (2017) Cohesin loss eliminates all loop domains. Cell 171(2):305–320. e324. https://doi.org/10.1016/j.cell.2017.09.026
Wutz G, Varnai C, Nagasaka K et al (2017) Topologically associating domains and chromatin loops depend on cohesin and are regulated by CTCF, WAPL, and PDS5 proteins. EMBO J 36(24):3573–3599. https://doi.org/10.15252/embj.201798004
Schwarzer W, Abdennur N, Goloborodko A et al (2017) Two independent modes of chromatin organization revealed by cohesin removal. Nature 551(7678):51–56. https://doi.org/10.1038/nature24281
Liu J, Krantz ID (2008) Cohesin and human disease. Annu Rev Genomics Hum Genet 9:303–320. https://doi.org/10.1146/annurev.genom.9.081307.164211
Li X, Zhang TW, Tang JL et al (2015) Loss of STAG2 causes aneuploidy in normal human bladder cells. Genet Mol Res 14(1):2638–2646. https://doi.org/10.4238/2015.March.30.24
Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E et al (2013) Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 45(12):1464–1469. https://doi.org/10.1038/ng.2799
Kim JS, He X, Orr B et al (2016) Intact cohesion, anaphase, and chromosome segregation in human cells harboring tumor-derived mutations in STAG2. PLoS Genet 12(2):e1005865. https://doi.org/10.1371/journal.pgen.1005865
Richart L, Lapi E, Pancaldi V et al (2021) STAG2 loss-of-function affects short-range genomic contacts and modulates the basal-luminal transcriptional program of bladder cancer cells. Nucleic Acids Res 49(19):11005–11021. https://doi.org/10.1093/nar/gkab864
De Koninck M, Lapi E, Badia-Careaga C et al (2020) Essential roles of Cohesin STAG2 in mouse embryonic development and adult tissue homeostasis. Cell Rep 32(6):108014. https://doi.org/10.1016/j.celrep.2020.108014
Solomon DA, Kim JS, Bondaruk J et al (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45(12):1428–1430. https://doi.org/10.1038/ng.2800
Lelo A, Prip F, Harris BT et al (2018) STAG2 is a biomarker for prediction of recurrence and progression in papillary non-muscle-invasive bladder cancer. Clin Cancer Res 24(17):4145–4153. https://doi.org/10.1158/1078-0432.CCR-17-3244
Taber A, Park Y, Lelo A et al (2021) STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urol Oncol 39(7):438 e431–438 e439. https://doi.org/10.1016/j.urolonc.2021.02.007
Acknowledgments
This work was supported by NIH grants R01CA169345 and R01CA267872 (to TW), The Children’s Cancer Foundation (to TW), and the Lombardi Cancer Center Support Grant P30CA051008.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Park, Y. et al. (2023). Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry. In: Hoffmann, M.J., Gaisa, N.T., Nawroth, R., Ecke, T.H. (eds) Urothelial Carcinoma. Methods in Molecular Biology, vol 2684. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3291-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3291-8_8
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3290-1
Online ISBN: 978-1-0716-3291-8
eBook Packages: Springer Protocols